Sleep

Dupilumab is the first treatment in the US indicated for adults and pediatric patients over 12 years with EoE.

Results from the 2 APPaRENT trials suggest regular inhaled corticosteroids/LABA alone or with short-acting beta agonists were the preferred treatment approach with physicians.

The new study provides insights into the physiological factors for greater AtoOxy efficacy and can be referenced when identifying patients who are most suited for the therapy.

Patients with a positive family history of OSA tended to be female with more severe OSA based on a higher AHI.

Obstructive sleep apnea has previously been associated with pulmonary hypertension in literature, with investigators citing a “complex and bidirectional relationship” between the 2 conditions.

Investigators from this ATS session suggested THN therapy could be used to treat OSA, believing in to be “a simpler approach than incumbent technology with no sensor and an easier, proximal electrode implantation”.

Dr. Rizzo sits down with HCPLive to discuss the impact of air pollution and allergies on pulmonary health, as well as new research on pulmonary arterial hypertension.

The prevalence of sleep-disordered breathing differed across various etiologies of heart failure.

Previously, the US Preventive Services Task Force reviewed screening evidence for COPD in 2016 and issued a D recommendation against screening in asymptomatic adults.

Sleep disordered breathing is frequently cited in patients with heart failure due to multiple factors included hypoxemia, sympathetic activation and systematic inflammation.

New interim data from the RESTORE study indicates that more than 94% of participants preferred the once-nightly dosing of FT218.

Currently, CPAP is the first-line therapeutic option for OSA. Despite this, investigators noted that many patients with OSA do not tolerate CPAP therapy.

Upper airway stimulation was initially shown to be effective in adults with obstructive sleep apnea.

The VersiPD Cycler System is expected to be available in the US in 2022.

Investigators hypothesize that the development of culturally tailored interventions could prove beneficial for engaging racial and ethnic minority patients with data-driven insomnia treatment.

New data suggests that symptoms of depression are screened in addition to symptoms of insomnia in affected patients.

About 1 in 5 recent novel drug approvals were based on data extrapolated to a broader patient population or in regard to a concomitant drug use, including the controversial aducanumab indication from 2021.

Students who reported maltreatment had 2.47 times the odds of receiving an insomnia diagnosis than those without adverse childhood experiences.

Investigators found that sleep apnea was also associated with an increased risk of Parkinsons disease.

An association between REM-OSA and intima thickness was also observed in women patients.

Conversely, insomnia was associated with an increased risk of prostate cancer.

The prevalence of short and long sleep duration were considerably higher among Black individuals during the 15-year study period.

New data shows that FT218 demonstrated clinically meaningful improvements regarding disrupted nighttime sleep compared to placebo in adults with narcolepsy.

The survey – the largest of its kind- found that 70% of people with trouble sleeping or insomnia reported being “desperate to find a solution”.

The use and legalization of cannabis products has been increasing in the US for a variety of medical concerns. Investigators aim to better understand the risks and benefits of owning a medical marijuana card.

The hope is society learns some of the lessons from the Cold War to better help patients with mental health concerns.

Social media has had an influence on the mental health toll the war in the Ukraine is having.

Digital cognitive behavioral therapy for insomnia was the better option to patient education on all ratings for patients with self-reported morning or intermediate chronotypes.

New data on FT218 will be presented at the World Sleep 2022 conference in Rome.